title: Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.
abstract: We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (<35% Ph-negative marrow metaphases) at 3 months as principal independent predictive factors and incorporated them into a three-tier prognostic scoring system for individual patients. For patients in the low-, intermediate- and high-risk groups, the probabilities of survival at 24 months were 100, 82 and 40% (P<0.0001) and progression-free survival 100, 66 and 15% (P<0.0001), respectively. This Hammersmith prognostic scoring system was validated with an independent cohort of patients treated at another UK centre.
authors.affiliation: Department of Haematology, Imperial College London at Hammersmith Hospital, London, UK.
authors.forename: D
authors.initials: D
authors.lastname: Marin
authors.forename: S
authors.initials: S
authors.lastname: Marktel
authors.forename: M
authors.initials: M
authors.lastname: Bua
authors.forename: R M
authors.initials: RM
authors.lastname: Szydlo
authors.forename: A
authors.initials: A
authors.lastname: Franceschino
authors.forename: I
authors.initials: I
authors.lastname: Nathan
authors.forename: N
authors.initials: N
authors.lastname: Foot
authors.forename: C
authors.initials: C
authors.lastname: Crawley
authors.forename: T
authors.initials: T
authors.lastname: Na Nakorn
authors.forename: E
authors.initials: E
authors.lastname: Olavarria
authors.forename: A
authors.initials: A
authors.lastname: Lennard
authors.forename: A
authors.initials: A
authors.lastname: Neylon
authors.forename: S G
authors.initials: SG
authors.lastname: O'Brien
authors.forename: J M
authors.initials: JM
authors.lastname: Goldman
authors.forename: J F
authors.initials: JF
authors.lastname: Apperley
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides; D020732:Cytogenetic Analysis; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D018570:Risk Assessment; D016879:Salvage Therapy / Q000379:methods* / Q000401:mortality; D012720:Severity of Illness Index; D016019:Survival Analysis; D017211:Treatment Failure
chemical_list: D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate